Jinyu Bio-Technology's subsidiary has been approved to produce emergency foot-and-mouth disease vaccines for immunization.

Jinyu Bio-Technology (600201.SH) announced that its wholly-owned subsidiary, Jin Yu Bao Ling Biopharmaceutical Co., Ltd. (referred to as "Bao Ling Company"), has been authorized to produce emergency immune foot-and-mouth disease South African type 1 subunit vaccine and foot-and-mouth disease South African type 1 inactivated vaccine (Re-SAT1/2026 strain). South African type 1 foot-and-mouth disease is a type of acute highly contagious disease caused by the South African type 1 foot-and-mouth disease virus, which has a rapid onset, fast transmission, and great harm. It mainly infects animals such as cattle, sheep, and pigs. After the approval for the production of the South African type 1 foot-and-mouth disease vaccine, the company will actively cooperate with national epidemic prevention policies, accelerate emergency immunization work, organize production strictly in accordance with relevant requirements to ensure vaccine quality, and ensure the health and stability of the livestock industry.